HomePAI Pharma acquires Nexus Pharmaceuticals, expanding portfolio of sterile injectable products

PAI Pharma acquires Nexus Pharmaceuticals, expanding portfolio of sterile injectable products

PAI Pharma, has acquired Nexus Pharmaceuticals, a pharmaceutical company specialising in the development and commercialisation of injectable medicines used in critical care, oncology, and other hospital settings.

The acquisition marks another significant step in PAI’s strategy to build a broader portfolio of essential medicines and expand its presence in the hospital and sterile injectable markets.

Nexus brings an established commercial portfolio of over 20 hospital injectable products, deep customer relationships, and extensive expertise in developing and commercialising critical therapies.

Combined with PAI’s leadership in Ready-to-Dose oral liquid medicines and growing sterile injectable business, including the recent acquisition of Nivagen and its aseptic manufacturing capabilities in Sacramento, the acquisition strengthens PAI’s ability to serve hospitals and healthcare providers with a broader range of high-quality pharmaceutical products.

- Advertisment -
- Advertisment -

Most Popular

Popular categories